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Abstract
Background Cardiac cachexia frequently accompanies the progression of heart failure despite the use of effective therapies
for left ventricular dysfunction. Activation of the sympathetic nervous system has been implicated in the pathogenesis of
weight loss, but the effects of sympathetic antagonism on cachexia are not well deﬁned.
Methods We prospectively evaluated changes in body weight in 2289 patients with heart failure who had dyspnoea at rest
or on minimal exertion and a left ventricular ejection fraction <25%. Patients were randomly assigned (double-blind) to re-
ceive either placebo (n = 1133) or carvedilol (n = 1156) and were followed for the occurrence of major clinical events for
up to 29 months (COPERNICUS trial). Patients were not enrolled if they had signs of clinically signiﬁcant ﬂuid retention due
to heart failure.
Results Patients in the carvedilol group were 33% less likely than patients in the placebo group to experience a further sig-
niﬁcant loss of weight (>6%) (95% conﬁdence interval: 14–48%, P = 0.002) and were 37% more likely to experience a signif-
icant gain in weight (≥5%) (95% conﬁdence interval: 12–66%, P = 0.002). Carvedilol’s ability to prevent weight loss was most
marked in patients with increased body mass index at baseline, whereas its ability to promote weight gain was most marked in
patients with decreased body mass index at baseline. Increases in weight were not accompanied by evidence of ﬂuid reten-
tion. Baseline values for body mass index and change in body weight were signiﬁcant predictors of survival regardless of
treatment.
Conclusions Carvedilol attenuated the development and promoted a partial reversal of cachexia in patients with severe
chronic heart failure, supporting a role for prolonged sympathetic activation in the genesis of weight loss.
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Introduction
Loss of weight is common in patients with untreated chronic
heart failure and appears to happen early in the course of the
disease. The weight loss affects all body compartments, and
is important because muscle bulk is strongly related to
exercise capacity, and hence a patient’s symptoms,1 and be-
cause both decreasing weight and weight loss are strongly re-
lated to an adverse prognosis.2
Cachexia is used to describe involuntary weight loss sec-
ondary to disease states. Any deﬁnition requires an arbitrary
cut-off, and a commonly used deﬁnition is weight loss of at
OR IG INAL ART ICLE
© 2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle (2017)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12191
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
least 5% in 12 months.3 Cachexia accompanies a number of
disease states, including heart failure, and is associated with
a particularly poor prognosis. Although the causes of weight
loss and ultimately cachexia are not clear, the sympathetic
nervous system is activated in cachectic patients and has
been implicated in the development of muscle wasting.4–6
Uncontrolled reports have suggested that β-adrenergic block-
ade can attenuate muscle catabolism and lead to weight gain
in selected patients with cardiac and non-cardiac disorders,7
and other work has suggested that other agents that inter-
fere with neurohormonal activation in heart failure, such as
angiotensin converting enzyme inhibitors, are also associated
with a lower risk of weight loss.8
We wanted to explore the effects of sympathetic block-
ade on cardiac cachexia in a prospectively designed sub-
study of a large-scale clinical trial of the α1-/β1-/β2-receptor




We prospectively evaluated the patients enrolled in the Carve-
dilol Prospective Randomized Cumulative Survival
(COPERNICUS) trial, the design and primary results of which
have been previously published.9 A total of 2289 patients with
dyspnoea at rest or on minimal exertion and a left ventricular
ejection fraction<25% despite appropriate therapy were ran-
domly assigned (in a double-blind fashion) to receive either
placebo (n = 1133) or carvedilol (n = 1156) and were followed
for the occurrence ofmajor clinical events for up to 29months.
Patients were not enrolled if they had signs of clinically signif-
icant ﬂuid retention (rales, ascites, or more than minimal pe-
ripheral oedema) at the time of randomization, unless the
ﬂuid retention was deemed due to of a non-cardiac cause.
Following randomization, patients received an initial dose
of 3.125 mg of placebo or carvedilol twice daily for 2 weeks,
which was then increased at 2-week intervals (if tolerated),
ﬁrst to 6.25 mg, then to 12.5 mg, and ﬁnally to a target dose
of 25 mg twice daily. Each patient then entered a mainte-
nance phase, during which they were seen every 2 months
until the end of the study. Height and weight were measured
at baseline, and weight was measured every 2 weeks during
up-titration and every 2 months during the maintenance
phase. Throughout the trial, investigators were encouraged
to adjust the dose of concomitant diuretic continually to
maintain euvolemia and dry weight.
Statistical analysis
The primary endpoint of COPERNICUS was all-cause mortal-
ity. A detailed analysis of the prognostic importance of and
the effect of treatment on weight loss was prospectively de-
ﬁned prior to completion of the trial.
Patients in the trial were grouped according to their base-
line body mass index (deﬁned as weight [in kilogrammes] di-
vided by the square of the height [in metres]) into the
following pre-speciﬁed categories: <22 kg/m2 (underweight),
22 to <25 kg/m2 (ideal weight), 25 to <30 kg/m2 (over-
weight), and ≥30 kg/m2 (obese). Five patients with missing
Table 1 Baseline characteristics of patients in body mass index subgroups
Baseline body mass index (kg/m2)
<22 22 to <25 25 to <30 ≥30
Number of patients 279 (12.3%) 567 (25.1%) 932 (41.2%) 484 (21.4%)
Age (years)* 67.4 ± 12.1 64.5 ± 11.6 63.1 ± 10.8 59.7 ± 11.1
Gender (% men)* 70.3 82.2 82.0 78.1
Duration of heart failure (years) 2.5 ± 2.7 2.7 ± 3.4 2.7 ± 3.2 2.6 ± 2.7
Ischaemic aetiology (%)* 61.3 71.4 69.6 60.3
LV ejection fraction (%) 19.1 ± 4.4 19.8 ± 3.8 20.0 ± 3.6 20.0 ± 4.5
Heart rate (beats/min)* 83.1 ± 12.7 82.1 ± 12.7 81.9 ± 11.7 85.5 ± 12.9
Systolic BP (mmHg)* 115.2 ± 18.1 120.3 ± 17.9 125.3 ± 18.3 127.9 ± 19.1
Diastolic BP (mm Hg)* 72.1 ± 10.1 74.8 ± 10.6 77.1 ± 10.4 79.6 ± 11.4
Serum sodium (mmol/L) 137.0 ± 2.8 136.7 ± 2.8 136.8 ± 2.6 137.0 ± 2.8
Serum creatinine (μmol/L)* 136.8 ± 43.4 134.9 ± 38.3 134.3 ± 33.3 128.6 ± 34.5
Haemoglobin (g/dL)* 13.3 ± 1.7 13.8 ± 1.8 14.0 ± 1.6 14.1 ± 1.8
Concomitant medications (%):
Digitalis* 76.3 67.5 61.9 65.5
Diuretics 98.9 98.4 99.5 99.2
ACEI/ATII* 94.3 97.4 97.3 98.8
Spironolactone 20.1 20.6 18.0 20.7
Amiodarone 17.2 19.6 16.5 16.9
ACEI/ATII = angiotensin converting enzyme inhibitor or angiotensin II antagonist; BP = blood pressure; LV = left ventricular. Continuous
data are expressed as means ± standard deviations.
*Differences are statistically signiﬁcant among subgroups (P < 0.05).
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baseline values for height or weight and 22 patients with oe-
dema at baseline were excluded from all analyses as were
any weights recorded during follow-up if oedema were pres-
ent (4.8% of 18 448 weight measurements). Baseline charac-
teristics among the four subgroups for body mass index were
compared using the Kruskal–Wallis test for continuous vari-
ables and the chi-squared test for categorical variables.
The effect of treatment on change in body weight was
evaluated at each visit using the Wilcoxon rank sum test.
We deﬁned loss of body weight from baseline of >6% as be-
ing important weight loss: we chose to use a higher cut-off
than the more usual 5% to be certain we were only includ-
ing signiﬁcant change in weight given that weight may ﬂuc-
tuate in patients with chronic heart failure because of
Figure 1 Kaplan–Meier cumulative incidence curves for all-cause mortality in subgroups deﬁned by pre-treatment body mass index (BMI) (placebo
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changes in ﬂuid status. Gain in body weight of ≥5% from
baseline was deﬁned as clinically signiﬁcant. The time to
these weight-change events was estimated using linear in-
terpolation between weight measurements, and follow-up
time for patients with no event was censored on the date
of the last recorded weight measurement.
Cumulative incidence curves for all-cause mortality and
weight change events were constructed by the Kaplan–
Meier method. The relationships between pre-treatment
body mass index, the effect of treatment with carvedilol,
and the risk of clinical events were examined using Cox
proportional hazards regression models with pre-treatment
body mass index included as a continuous variable. A treat-
ment group by pre-treatment body mass index interaction
term was included in the models to assess the inﬂuence
of pre-treatment body mass index on the magnitude of
the treatment effect. These models were also used to esti-
mate hazard ratios and 95% conﬁdence intervals. The rela-
tionship between weight change during the study and all-
cause mortality was examined by including a time-
dependent covariate for weight change from baseline in
the Cox model, using interpolated weight values at each
failure time.
It should be noted that analyses of weight gain and
weight loss during the study ignore the competing risk of
death and the effect that differences in survival have on
the type of patient at risk across time. Considering the sur-
vival beneﬁt of carvedilol, however,9 these analyses are bi-
ased in favour of placebo and therefore underestimate any
effect of carvedilol.
All reported P values are two-sided and nominal.
Results
The baseline characteristics of subgroups deﬁned by baseline
body mass index are shown in Table 1. At the beginning of
the study, 279 patients (12.3%) were underweight (body
mass index <22), and 484 patients (21.4%) were obese (body
mass index ≥30). Patients who were underweight were most
likely to have the most advanced heart failure as reﬂected by
their greater age, higher heart rate and serum creatinine,
lower blood pressure and haemoglobin, and more frequent
use of digitalis and less frequent use of drugs interfering with
the renin–angiotensin system.
The lower the body mass index, the higher the risk of
death, regardless of treatment (Figure 1). For each unit in-
crease in body mass index, the risk of death decreased by
7.7% (P < 0.0001). Carvedilol reduced the risk of death by
35% (from 19.7 to 12.8 per cent per patient-year of follow-
up, P< 0.001), and the magnitude of this beneﬁt did not vary
as a function of pre-treatment body mass index (interaction P
value = 0.97, Figure 2).
Effect of carvedilol on changes in body weight
During the course of follow-up, patients in the carvedilol
group gained weight when compared with patients in the pla-
cebo group. The difference between the two groups became
statistically signiﬁcant approximately 6 months following ran-
domization and increased in magnitude with increased dura-
tion of follow-up (Figure 3). After approximately 1 year of
treatment, weight increased in carvedilol-treated patients
by 1.2 ± 0.2 kg, as compared with a slight loss of weight of
0.1 ± 0.2 kg in placebo-treated patients, P < 0.0001.
Figure 2 Hazard ratios and 95% conﬁdence intervals for the effect of car-
vedilol on all-cause mortality in subgroups deﬁned by pre-treatment
body mass index (BMI). Hazard ratios <1.0 indicate lower risk in the car-
vedilol group.
Figure 3 Mean change in body weight from baseline at speciﬁed times
during follow-up in the carvedilol (ﬁlled squares) or placebo (open
squares) groups. The P values denote signiﬁcance for the comparison be-
tween groups.
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Patients in the carvedilol group were less likely than
patients in the placebo group to experience a loss of weight
>6% during the course of follow-up (Table 2 and Figure 4).
A critical loss of weight occurred in 145 patients in the pla-
cebo group but only 110 patients in the carvedilol group—a
33% lower risk of clinically signiﬁcant weight loss due to
treatment with carvedilol (95% conﬁdence interval, 14–48%
lower risk, P = 0.002, Figure 3). The effect of carvedilol was
most marked in patients with an increased baseline body
mass index (Table 2).
Patients in the carvedilol group were more likely than pa-
tients in the placebo group to experience a gain in weight
of ≥5% (Table 2 and Figure 4). A critical gain in weight oc-
curred in 234 patients in the carvedilol group but in only
167 patients in the placebo group—a 37% greater likelihood
risk of clinically signiﬁcant weight gain as a result of treat-
ment with carvedilol (95% conﬁdence interval, 12–66% lower
risk, P = 0.002, Figure 3). The effect of carvedilol was most
marked in patients with a decreased body mass index at
baseline (Table 2).
Prognostic importance of weight changes
Although change in body weight during the study predicted
survival independent of treatment assignment (carvedilol
vs. placebo) or pre-treatment body mass index (data not
shown), comparison of the hazard ratios for treatment as-
signment in the model that included the time-dependent co-
variate for weight change (hazard ratio = 0.69) or did not
include weight change (hazard ratio = 0.65) suggested that
only a small portion of the beneﬁt of carvedilol on survival
was attributable to its effect on body weight.
Discussion
We have found strong evidence that one class of drugs with
established efﬁcacy in the treatment for heart failure (specif-
ically, beta-adrenergic blocking drugs) can ameliorate the
syndrome of cardiac cachexia. In a large-scale controlled clin-
ical trial, long-term treatment with carvedilol not only mark-
edly reduced the risk of further weight loss but also led to
meaningful reversal of cachexia in many patients with ad-
vanced left ventricular dysfunction.
The beneﬁcial effects of beta-adrenergic blockade on the
syndrome of cardiac cachexia are consistent with earlier re-
ports that postulated an important role for the sympathetic
nervous system in the development of cardiac cachexia (The
role of the sympathetic nervous system was reviewed in10).
Activation of the sympathetic nervous system is associated
with the development of cachexia in patients with can-
cer.11,12 Patients with heart failure have marked sympathetic
nervous system activation, and plasma norepinephrine is
even higher in heart failure patients with cachexia as com-
pared with heart failure patients without muscle wasting.7
Increased sympathetic activity can contribute to ca-
chexia by increasing total body energy expenditure,13
which can be reduced with β-blockade,14 and by exerting
direct myotoxic effects on skeletal muscle,15,16 again atten-
uated by beta-blockade.18 Blockade of β2-receptors seems
to have a more profound effect than blockade of β1-re-
ceptors.5,18 In addition, sympathetic activation can de-
crease the secretion of leptin,17 exacerbate insulin
resistance,18 and promote the release of proinﬂammatory
cytokines,19 all of which can lead to wasting of adipose
and muscle cells.
Beta-blockade is thus a logical approach to managing the
problem of weight loss and cachexia. Carvedilol’s ability to
prevent weight loss was most marked in patients who were
overweight at baseline, whereas its ability to promote weight
gain was most marked in patients who were underweight at
baseline. This difference between treatment groups was ap-
parent, even though patients were more likely to die on pla-
cebo, which would have been expected to minimize the
retention of high-risk cachectic patients in the placebo group.
The effects of carvedilol on cachexia were greater than those
previously reported with an angiotensin converting-enzyme
inhibitor8 but were seen in patients already receiving such
treatment. These data therefore represent the ﬁrst clinical
Table 2 Frequency of weight gain and weight loss during follow-up in the placebo and carvedilol groups
Baseline body mass index (kg/m2)
<22 22 to <25 25 to <30 ≥30
Weight gain ≥5%
Placebo 30/125 (31%) 50/278 (24%) 58/430 (21%) 29/229 (15%)
Carvedilol 60/136 (59%) 63/265 (30%) 74/453 (21%) 37/232 (25%)
Carvedilol:placebo hazard ratio (95% CI) 2.20 (1.41–3.43) 1.23 (0.85–1.79) 1.11 (0.79–1.57) 1.48 (0.91–2.41)
Weight loss >6%
Placebo 16/125 (19%) 34/278 (19%) 57/430 (17%) 38/229 (19%)
Carvedilol 16/136 (17%) 32/265 (17%) 41/453 (11%) 21/232 (11%)
Carvedilol:placebo hazard ratio (95% CI) 0.90 (0.44–1.81) 0.86 (0.53–1.40) 0.59 (0.39–0.88) 0.56 (0.33–0.96)
CI = conﬁdence interval. These analyses are restricted to patients with at least one weight measurement during follow-up (n= 2148) and
do not account for the risk of death as a competing factor. Percentages are 1-year Kaplan–Meier event rates.
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trial demonstrating that the development of cardiac cachexia
can be both slowed and ameliorated in patients with chronic
heart failure.
Our results are similar to those seen more recently results
in a trial of beta-blockade in patients with cachexia due to
cancer. In ACT ONE, the beta-blocker espindolol was given
to 87 patients with cancer-related cachexia for 16 weeks in
a randomized, double blind, trial.20,21 Patients who received
higher dose espindolol gained weight whilst patients on pla-
cebo continued to lose weight. There was a signiﬁcant in-
crease in lean body mass, rather than fat mass, and there
was a suggestion that higher dose espindolol was associated
with a better prognosis.
There is an extensive literature on the ‘obesity paradox’ of
heart failure—that is, the apparently paradoxical relation be-
tween increasing weight and better survival. The relation
Figure 4 Kaplan–Meier cumulative incidence curves for the occurrence of at least a 5% weight gain and for greater than 6% weight loss in the placebo
and carvedilol groups. Patients treated with carvedilol were 37% more likely to experience signiﬁcant weight gain (P = 0.002) and 33% less likely to
experience signiﬁcant weight loss (P = 0.001).
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between increasing weight and improved prognosis has been
shown both in patients with chronic22 and those with acute
heart failure.23 It may be that the apparent paradox is (at
least in part) an artefact: studies have been retrospective; pa-
tients who are obese may become breathless earlier (and
hence present earlier) than those with normal weight; and
obese patients by virtue of higher blood pressure might be
better able to tolerate higher doses of disease-modifying
medication. However, weight loss is also associated with a
poor prognosis, particularly in those patients who are obese
at baseline.24
Limitations
Our ﬁndings should be interpreted cautiously for two rea-
sons. First, as has been performed in earlier reports, cachexia
was deﬁned as changes in body weight, but changes in
weight can be related to shifts in ﬂuid, particularly in patients
with heart failure. This possibility led us to exclude from our
analyses any data collected at times when patients experi-
enced clinically important ﬂuid retention. Such exclusion oc-
curred infrequently, however, because patients with pre-
existing ﬂuid retention were excluded (by protocol design)
at the start of the study and because investigators were
strongly encouraged to adjust the dose of concomitant di-
uretic continually to maintain dry weight throughout the trial.
Second, the effects of carvedilol on body weight may not
have reﬂected a speciﬁc adrenergic effect on the metabolism
of adipose tissue or skeletal muscle but may have been re-
lated to an increase in physical activity25,26 or improvement
in nutrition27 that might accompany a reduction in symptoms
in heart failure. However, exercise tolerance has not been
consistently improved with carvedilol in clinical trials in heart
failure,28–30 and treatments that have improved symptoms
and exercise tolerance have not produced striking effects
on cachexia.
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